Back
ESC Premium Access

Effects of the GLP-1 receptor agonist, semaglutide, on heart failure outcomes: a pre-specified analysis of the FLOW trial in participants with type 2 diabetes and chronic kidney disease

Session: Clinical trial updates on the GLP-1 receptor agonist, semaglutide
Topic: Pharmacotherapy
Speaker: Doctor R. Pratley (Orlando, US)
Event: ESC Congress 2024

Congress Presentation

Add to my library

Like

About the speaker

Doctor Richard Pratley

AdventHealth Orlando, Orlando (United States of America)
1 presentation
0 follower

7 more presentations in this session

Atrial fibrillation and efficacy of semaglutide 2.4 mg in obesity-related HFpEF: A Patient Level Pooled analysis of STEP-HFpEF and STEP-HFpEF DM trials

Speaker: Doctor M. Kosiborod (Kansas City, US)

Access
Slides
Video
Like
Thumbnail

Inflammation in obesity-related HFpEF: the STEP-HFpEF programme

Speaker: Professor S. Verma (Toronto, CA)

Access
Slides
Video
Like
Thumbnail

STEP-HFpEF Program Echocardiography Substudy

Speaker: Professor S. Solomon (Boston, US)

Access
Slides
Video
Like
Thumbnail

Effects of semaglutide on clinical events in heart failure with preserved ejection fraction: a pooled, participant-level analysis of SELECT, FLOW, STEP-HFpEF and STEP-HFpEF DM trials

Speaker: Doctor M. Kosiborod (Kansas City, US)

Access
Slides
Video
Like
Thumbnail

Semaglutide and cardiovascular outcomes in females with overweight and obesity: A prespecified analysis of the SELECT trial

Speaker: Professor S. Verma (Toronto, CA)

Access
Slides
Video
Like
Thumbnail

Access the full session

Clinical trial updates on the GLP-1 receptor agonist, semaglutide

Speakers: Doctor R. Pratley, Doctor M. Kosiborod, Professor S. Verma, Professor S. Solomon, Doctor M. Kosiborod...
Access
Video
Like
Thumbnail

About the event

Image

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources